Prognostic Significance of Matrix Metalloproteinase-9 (MMP-9) in Epithelial Ovarian Cancer
Overview
Authors
Affiliations
Objective: We investigated the expression of matrix metalloproteinase-9 (MMP-9) and its relation to clinicopathologic factors and survival and also to previously analyzed expressions of CD44 and hyaluronan in epithelial ovarian cancer.
Methods: The expression of MMP-9 was analyzed immunohistochemically in 292 primary tumors and their 31 metastases.
Results: A low proportion of strong MMP-9 expression in cancer cells and high stromal MMP-9 expression correlated with advanced stage of the tumor (p=0.003, p=0.02, respectively). Stromal MMP-9 expression significantly correlated with hyaluronan positivity (p<0.0005), whereas MMP-9 did not correlate with CD44. In univariate analysis, a longer 10-year disease-related survival (DRS) was found in patients with a high proportion of MMP-9 or strong MMP-9 expression in cancer cells (p=0.02, p=0.05, respectively). However, high stromal expression of MMP-9 indicated short DRS (p=0.01). In multivariate analysis of all patients, MMP-9 expressing cancer or stromal cells were not independent prognostic factors, while in FIGO stage I patients a high percentage of MMP-9 positive cancer cells was associated with long DRS (p=0.008).
Conclusion: These data suggest that MMP-9 has a dual role in tumor progression, acting against tumor advancement when in tumor epithelium and promoting tumor progression while in the stroma.
De Silva S, Alli-Shaik A, Gunaratne J Sci Data. 2024; 11(1):685.
PMID: 38918474 PMC: 11199488. DOI: 10.1038/s41597-024-03536-1.
Tavassoli N, Ghahremani A, Namakin K, Naserghandi A, Miri S, Abdolahad M Ther Hypothermia Temp Manag. 2023; 14(4):290-298.
PMID: 38079194 PMC: 11665270. DOI: 10.1089/ther.2023.0060.
Tsukamoto S, Koma Y, Kitamura Y, Tanigawa K, Azumi Y, Miyako S Cancers (Basel). 2023; 15(11).
PMID: 37296952 PMC: 10252039. DOI: 10.3390/cancers15112987.
Schossig P, Coskun E, Arsenic R, Horst D, Sehouli J, Bergmann E Int J Mol Sci. 2023; 24(3).
PMID: 36768616 PMC: 9916968. DOI: 10.3390/ijms24032292.
Kicman A, Niczyporuk M, Kulesza M, Motyka J, Lawicki S Cancer Manag Res. 2022; 14:3359-3382.
PMID: 36474934 PMC: 9719685. DOI: 10.2147/CMAR.S385658.